Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process: 2023-2024

Historic Work In Process for Krystal Biotech (KRYS) over the last 2 years, with Dec 2024 value amounting to $10.7 million.

  • Krystal Biotech's Work In Process rose 147.28% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 147.28%. This contributed to the annual value of $10.7 million for FY2024, which is 235.30% up from last year.
  • Per Krystal Biotech's latest filing, its Work In Process stood at $10.7 million for FY2024, which was up 235.30% from $3.2 million recorded in FY2023.
  • Over the past 5 years, Krystal Biotech's Work In Process peaked at $10.7 million during FY2024, and registered a low of $3.2 million during FY2023.
  • For the 2-year period, Krystal Biotech's Work In Process averaged around $7.0 million, with its median value being $7.0 million (2023).
  • Data for Krystal Biotech's Work In Process shows a peak YoY spiked of 235.30% (in 2024) over the last 5 years.
  • Krystal Biotech's Work In Process (Yearly) stood at $3.2 million in 2023, then surged by 235.30% to $10.7 million in 2024.